Contact
QR code for the current URL

Story Box-ID: 616998

SIRION BIOTECH GmbH Am Klopferspitz 19 82152 Martinsried, Germany https://www.sirion-biotech.de
Contact Mr Dieter Lingelbach +49 89 12017222
Company logo of SIRION BIOTECH GmbH
SIRION BIOTECH GmbH

Novel full-range lentivirus platform from widely accessible core facility

Working with lentivirus experiences new heights with latest launches by SIRION Biotech

(PresseBox) (Munich / New Hampshire / Tokyo, )
SIRION Biotech announced today its novel lentivirus portfolio for the most sophisticated in vitro applications. Besides its (1) non-toxic transduction enhancer coined LentiBOOST(TM) , SIRION Biotech offers (2) premade lentivirus vectors and (3) custom ser-vices. The latter allows for all possible modifications and applications ranging from complex and multiple genes expression to TET- inducible all-in-one vectors; lentivirus particles can be ordered directly or as basis for an entire cell line production. The finished cell lines come virus free and ready-to-use.

Genetic modification is a prerequisite for today's target research and cell based assay screening for compound development. Viral vectors work both in vitro and in vivo, are versatile and warrant high gene delivery rates: The viruses' own infection machinery is being used to transport genetic material into the host cells. Several viral vector platforms are in use: lentivirus lends itself to sta-ble gene modifications as opposed to transient modifications like with adenovirus (AV) and adeno-associated virus (AAV).

Specialized service providers like SIRION Biotech are able to provide custom lentivirus and the resulting stable cell pools within a matter of weeks, premade lentiviral particles can be shipped literally over night. The availability of such focused services allows for faster and more reliable research. Viral vector technologies are applicable from drug discovery to food sciences and cosmetics developments.

Website Promotion

Website Promotion
SIRION Biotech - Viral Vector Core Facility

SIRION BIOTECH GmbH

SIRION Biotech was founded in Munich in 2006 with the idea of enabling novel cell models clos-er to reality than ever before. This required the assembly of an all-encompassing, novel viral vector platform. Both, designing de novo viral vectors and the subsequent creation of custom cell models will pave the way for superior compound development in the life sciences. SIRION's technologies have been validated in over 300 single projects with more than 100 academic and industrial partners. As a result, cell models for drug discovery and development have become highly reliable, as have the use of new viral vectors in gene therapy and vaccine studies.

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2024, All rights reserved

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.